GBSX MARIZYME BIOTECH MERGER! NVSOS NAME CHANGE AND MERGE IN JUST DONE! https://nvsos.gov/sosentitysearch/corpActions.aspx?lx8nvq=3ZnpU8XWHML%252b4rmlz34uaA%253d%253d&CorpName=MARIZYME%2c+INC TIMETABLE SUMMARY OF CURRENT AND UPCOMING EVENTS: CEO Joerg Ott Overview:
Marizyme is a biotechnology company with clinically tested and patented use of proteolytic enzyme therapy for the treatment of chronic wounds, thrombolysis and dental health.
Krillase® has been classified as a Class III medical device in Europe for treating chronic wounds and application patents have been granted for multiple other areas including thrombosis and dental health.
Patents: Multiple Applications: WO 2008/070698 A1 (June 12, 2008), Also EP2007/086455, US20110135625 Multiple Applications: US 7,947,270 B2 (May 24 2011) Wound Healing: WO 2013/149809 A1 (October 10, 2013) Thrombolysis (Pending): EP 15004350.2 (December 4, 2015) Dental Health: US 12/741,781 (December 30, 2010) Also Published as: WO 2009/060013 A2,A3 and EP 2217266 A2 European Approvals: TUV: Class III Medical Device for Wound Care (July 11, 2005) Filing Contacts: Renata Materna, email@example.com http://marizyme.com/about-us/ TINY FLOAT MEANS HUGE ROOM TO RUN HERE TO DOLLARS!